Justin Brandt, Founding Partner, Bianchi & Brandt, says that mainstream medicine’s embrace of psilocybin is inevitable as ongoing clinical research expands our understanding of its therapeutic benefits for various mental health conditions like PTSD, depression and addiction. He told DDW: “Meanwhile, the regulatory landscape for psilocybin and other psychedelics is rapidly evolving around the globe, with Australia leading the way by formally recognising psilocybin as medication. But other countries, including the US, Canada, and Israel, are also progressing in this regard. The overall shift in public perception, coupled with a growing body of clinical data, is driving further research aimed at addressing safety and efficacy. In the context of drug discovery, we’re navigating what is a perfect storm for expediting the formulation and standardisation of psilocybin for mainstream prescription therapies.”

Click here to read the full article